NCT05187858

A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

A Phase I Open-Label Study of LNP3794 (BI3011441) in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Lupin Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase I, open-label, dose escalation study of LNP3794 (BI3011441) in subjects with NRAS/KRAS mutated advanced or metastatic refractory solid tumors. The purpose of this study is to evaluate the safety/tolerability, pharmacokinetic and pharmacodynamic profile of the orally administered LNP3794 (BI3011441) as monotherapy at selected dose levels.

Conditions

• NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

Interventions

Type	Name	Description
DRUG	LNP3794	LNP3794 capsules administered orally once daily

Timeline

• Start date: 2020-09-22
• Primary completion: 2022-02-23
• Completion: 2022-06-30
• First posted: 2022-01-12
• Last updated: 2023-03-17

Locations

4 sites across 3 countries: Belgium, Netherlands, United Kingdom